Human induced pluripotent stem cells (hiPSCs) have a number of potential applications in stem cell biology and regenerative medicine, including precision medicine. However, their potential clinical application is hampered by the low efficiency, high costs, and heavy workload of the reprogramming process. Here we describe a protocol to reprogram human somatic cells to hiPSCs with high efficiency in 15 d using microfluidics. We successfully downscaled an 8-d protocol based on daily transfections of mRNA encoding for reprogramming factors and immune evasion proteins. Using this protocol, we obtain hiPSC colonies (up to 160 ± 20 mean ± s.d (n = 48)) in a single 27-mm 2 microfluidic chamber) 15 d after seeding~1,500 cells per independent chamber and under xeno-free defined conditions. Only~20 µL of medium is required per day. The hiPSC colonies extracted from the microfluidic chamber do not require further stabilization because of the short lifetime of mRNA. The high success rate of reprogramming in microfluidics, under completely defined conditions, enables hundreds of cells to be simultaneously reprogrammed, with an~100-fold reduction in costs of raw materials compared to those for standard multiwell culture conditions. This system also enables the generation of hiPSCs suitable for clinical translation or further research into the reprogramming process.
Introduction
The discovery that adult human somatic cells can be reprogrammed to pluripotency 1 has enabled previously inaccessible processes of human biology to be studied in vitro, and new personalized biomedical applications to be envisioned in vivo.
Somatic cell reprogramming can be induced by the forced expression of POU5F1 (OCT4), SOX2, KLF4 and C-MYC (OSKM; known as Yamanaka's factors) 1 . In the initial stage of reprogramming, the exogenous expression of these transcription factors perturbs the transcriptional network of somatic cells. In response, cells integrate intrinsic and extrinsic cues to remodel chromatin and reach a new epigenetic state. The latter stages of reprogramming, maturation and stabilization, result in the endogenous expression of the core circuitry of pluripotency.
We aimed to develop a protocol for the cost-effective production of quality-controlled human pluripotent stem cells in non-integrating and chemically defined xeno-free culture conditions. The method we developed enables reprogramming of a limited number of human somatic cells with high efficiency, high throughput, and low costs to produce hiPSCs without genomic integration 2 . We achieved these results by downscaling mRNA-based cell reprogramming, using microfluidics to miniaturize the system. Here we describe in detail how to set up and use our miniaturized system.
Development of the protocol
Miniaturization results in an~50-fold increase of efficiency compared with that of conventional culture systems, even under defined xeno-free conditions 2 . Miniaturization provides two substantial advantages: a notable improvement in mRNA delivery, as a consequence of the short distance between the synthetic mRNA and the cells 2 ; and a faster accumulation of cellular extrinsic endogenous factors that positively feed back on cellular reprogramming (Fig. 1 ). This self-regulation of the cellular microenvironment promotes the conversion of fibroblasts to hiPSC colonies only when a critical ratio between cell density and medium height is used 2 .
This protocol utilizes the advantages of mRNA reprogramming in standard systems, such as the rapidity of exogenous mRNA clearance due to the~24-h life span of mRNA in the cells 3 . In microfluidics, after only 15 d of reprogramming, a high number of hiPSC colonies are obtained (up to 160 ± 20 mean ± s.d (n = 48)) hiPSC colonies per culture chamber). These colonies can then be extracted from the setup and used for other applications.
The miniaturization of this protocol also offers specific advantages. First, a low number of cells is required (~1,600 cells per chamber). Thus, this protocol can be used when there is limited availabilityv of biological samples, for example, when using primary cells or when cell expansion and cell senescence prevent successful reprogramming. Second, in a single microfluidic device, ten independent parallel experiments can be performed, greatly increasing the experimental throughput. A single operator can easily manage 100 parallel reprogramming experiments with a normal workload. Third, the small volume of the system (~5 μL) reduces the cost of reagents >100-fold and has a considerable effect on the feasibility of reprogramming on a large scale. Many conditions of reprogramming can be tested for a single cell line to increase the reprogramming success rate, as discussed below; somatic cells from large cohorts of patients can be affordably reprogrammed; and multiparametric optimization becomes possible for the development of integrated processes of reprogramming and differentiation 2, [4] [5] [6] . The protocol we describe here has been improved compared with that used in our original publication 2 . Previously, the reprogramming was based on a daily transfection of modified mRNAs (OCT4, SOX2, KLF4, C-MYC, NANOG, LIN28 (OSKMNL)) for at least 12 d. Moreover, the transfections were coupled with two changes per day of medium supplemented with B18R protein, to reduce interferon response. Medium was freshly prepared each day, and reprogramming was performed in normoxia. This protocol was highly effective but required a heavy workload during the entire duration of the reprogramming, which could last up to 15 d. Thus, we further optimized the protocol to reduce its complexity in terms of medium preparation and to reduce the overall number of medium changes and transfections, while maintaining the high reprogramming efficiency.
The improved version of the protocol we describe here enables microfluidic reprogramming based on commercially available nonmodified mRNAs (NM-RNAs) of the same reprogramming factors (OSKMNL) combined with immune evasion NM-RNAs encoding E3, K3 and B18R protein (EKB), and two microRNAs (miRNAs) from the 302/367 cluster, previously reported in a published protocol 7 . The reprograming process is performed under hypoxia (5% (vol/vol) O 2 ), an established favorable factor to improve reprogramming efficiency 8 . To efficiently downscale the reprogramming in the microfluidic system, we limited the number of daily transfections to eight for the entire reprogramming, with a single medium change per day.
Moreover, we also adapted the reprogramming protocol to use chemically defined medium (E7 medium). E7 has the same components present in E8 9 (the widely used medium for hiPSC expansion), except that TGFβ is absent. It has a disclosed and simple composition, which makes it suitable accumulation from a standard well culture system to microfluidics. Endogenous and exogenous factor sizes are not to scale. b, Drawing of a ten-chamber microfluidic device during medium change by manual pipetting, and dimensions of a single channel-shaped microfluidic culture chamber. Cell size is not to scale.
for defined biological studies of cell reprogramming. Finally, we used a new method, based on the use of EDTA as a detachment agent, to selectively extract hiPSC colonies from microfluidic chambers.
Application of the protocol
Microfluidic reprogramming can be adapted to a wide range of applications. There are no major limitations in downscaling other reprogramming methods to the microfluidic system after optimizing the conditions. Moreover, given the feasibility of the production of customized mRNAs by common biological laboratories, the coupling of microfluidic and mRNA technologies provides great flexibility for other applications.
As an example, we performed fibroblast reprogramming in microfluidics also, using a different approach based on self-replicating RNAs of only four reprogramming factors, OCT4, KLF4, SOX2 and GLIS1. The results in Supplementary Fig. 1 show that cells can also be reprogrammed within this setup with only three Yamanaka factors and without c-MYC, with a consistent success rate in 20 independent microfluidic chambers.
Comparison with other methods
In recent years, numerous methods have been developed to generate hiPSCs, with the aim of increasing the efficiency of reprogrammed cells and also enabling the generation of footprint-free hiPSC lines that lack the integration of any viral vector sequences in their genomes. Replicationcompetent Sendai RNA virus carrying the Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) is widely used for skin fibroblast reprogramming 10 . It is relatively efficient, is highly reliable and has a low workload. However, the Sendai virus method does not allow flexibility in the expression level and stoichiometry of the reprogramming factors, and clearance of Sendai virus is relatively slow (>10 passages 11, 12 ). The substantial amount of work required to clear virus from the hiPSCs during expansion results in high costs for hiPSC colony stabilization. Episomal plasmids, which can be easily produced by single biological laboratories and provide process flexibility 13 , have been shown to have lower efficiency than Sendai virus, and the generated hiPSCs retain episomal plasmid sequences at high passages (>10) and have a high aneuploidy rate. Alternatively, a self-replicating RNA-based method has also been proposed 14 , but the complete clearance dynamics of the exogenous RNA, which is removed from the cells by the innate immune response, has not been investigated in a comparative study. These features discourage the use of these methods for clinical applications, which require hiPSCs of high quality.
The use of mRNA technology for reprogramming 15, 16 has advantages over other non-integrating reprogramming methods. Efficiency is up to 4%, and colonies emerge faster than with other methods. The aneuploidy rate is low, and there is a complete absence of cellular integration after fewer than 5 passages 11 . Moreover, mRNA can be easily produced by biological laboratories, which increases the flexibility of mRNA mix compositions, stoichiometry and level of expression. Specialized companies have already achieved clinical-grade mRNA transfection systems. As also reported in a recent benchmark study that compared the pros and cons of non-integrating methods 11 , reprogramming with mRNAs is the most promising approach to fully exploit the potential of hiPSC technology in clinical applications and research settings.
All methods for hiPSC derivation based on conventional culture systems (either Petri dish or multiwell) have considerably high costs, and this can be a limiting factor for many laboratories, especially when multiple patient samples need to be reprogrammed. For example, among the most popular integration-free methods, Sendai virus and mRNA approaches require expensive reagents for reprogramming. Moreover, high labor costs are associated with these methods, owing to the intensive expansion of either starting cells, used with low-efficiency methods, or hiPSCs, for which dilution and clearance of exogenous materials are necessary. For all these reasons, many researchers are limited to small numbers of simultaneous reprogramming experiments, which are often not sufficient to satisfy the need for multiple controls and multiple subject samples. For example, a six-sample hiPSC project, including three controls and three samples from affected subjects, costs more than €10,000 in reagents and requires one full-time researcher to generate hiPSCs. Characterization and clone selection further increase costs. In the best scenario, a recent comparative study showed that the highest efficiency of nonintegrating methods is ∼4% when mRNA is used 11 . Microfluidic reprogramming enables large-scale and high-efficiency production of high-quality hiPSCs. Microfluidic technology substantially decreases the cost of reagents and provides the highest efficiency among reprogramming methods. Using microfluidic reprogramming, we were able to generate an average number of 6 colonies/mm 2 in 15 d, which is higher than the yields of other methods reported in the literature, which range between 0.1 and 4 colonies/mm 2 in six-well plates 17 . Microfluidic reprogramming requires the seeding of a low number of cells, yet offers a high probability of obtaining colonies. Reprogramming-resistant cells can also be reprogrammed 2 . In addition, the cost of reagents can be decreased by~100-fold, as microfluidic platforms require only a few microliters of medium (a single chamber is~5 μL), and only a few nanograms of mRNA is required per day, compared to almost 2 μg when using standard conditions. Last, microfluidics is amenable to automation, offering the possibility of manipulating the microenvironment in a high-precision manner with remote control, thereby strongly reducing the workload and increasing the experimental throughput. Automation is important for large-scale production under strictly defined and clinicalgrade conditions. Recently, consortia such as the Human Induced Pluripotent Stem Cells Initiative (HipSci; http://www.hipsci.org) and the iPSC Repository of the California Institute for Regenerative Medicine (CIRM; https://www.cirm.ca.gov/researchers/ipsc-repository) have been formed to increase the availability of hiPSC lines. Cost reduction coupled with system automation make it possible to perform hundreds of parallel reprogramming experiments with different cell sources. Currently, even in manual mode, a single operator can easily manage 100 samples in parallel, using greatly reduced amounts of reagents.
Limitations
Reprogramming of different cell lines results in different success rates. This is a recognized problem in the field, and we have also experienced this limitation 2 . These differences can be ascribed to differences in primary fibroblast isolation protocols, fibroblast senescence and tissue of origin, and patient age and other patient-specific factors. Although understanding the origin of this variability is still incomplete, and the absolute reprogramming efficiency is quite variable, we found that microfluidics shows a great improvement in both success rate and number of colonies per cell seeded as compared with standard well culture systems. In the Troubleshooting section, adaptations of the protocol to increase the success rate on the basis of specific cell line behavior are discussed, but we recommend running different reprogramming conditions in parallel.
The small number of cells that can be cultured on each microfluidic chamber surface (whose area is typically <30 mm 2 ) could be limiting for methods of analysis that require a high number of cells, such as transcriptomic and proteomic characterizations. Pooled samples and the use of single-cell technologies can overcome this limitation.
mRNA reprogramming is labor intensive because of the need for daily transfections. However, there is a quick clearance of exogenous materials from the obtained hiPSCs. Using already-developed automation could further assist in protocol development and increase throughput 18 .
Experimental design
The workflow shown in Fig. 2 describes the main stages of the protocol (Boxes 1 and 2 and Steps 3-27). Four main tasks need to be undertaken, as discussed below.
Microfabrication (
Step 1, Box 1) Box 1 details the procedure for microfluidic device fabrication. A 'mask design' is provided in the Supplementary Manual, whose layout is shown in Supplementary Fig. 2 . Thus, a design stage is not needed, unless modifications to the proposed configuration are required. The 'master mold fabrication' is performed according to standard photolithographic techniques. It needs to be performed only once, as the master mold can be reused several times. If facilities are not available, it is advisable to outsource this work, providing an external company with the photomask. 'Microfluidic device Steps 3-9:
8 d
Steps 11-15: 4 h
Step 27A: 4 h
Step 27B production' refers to the standard soft-lithographic techniques used for the production of the microfluidic devices, called chips, made of polydimethylsiloxane (PDMS), and their attachment to a glass slide to build the final device. This step can be outsourced. Companies such as Onyel Biotech (Italy), or any other company that sells PDMS chips for long-term cell culture, can provide the microfluidic chip according to the protocol described in Box 1. We refer the reader to Box 1 and a previous protocol 19 for instructions on how to perform these first three parts of the current protocol. Final sterilization of the microfluidic devices can be performed by standard autoclaving.
Fibroblast culture in microfluidics (Step 2, Box 2) In Step 2 and Box 2, we provide advice on how to perform cell culture within microfluidic culture chambers. Before proceeding with a reprogramming experiment, we suggest following the protocol given in Box 2 to ensure that users become familiar with microfluidic technology and to verify the chip functionality. In particular, we describe how to perform the coating of the culture surface and how to change media. By following the explanations in Fig. 3 and Supplementary Video 1, one can carry out microfluidic culture efficiently, without bubble formation or evaporation of the medium.
Sequential RNA transfections (Steps 3-9)
This part of the protocol includes daily transfections of mRNA mix for a period of 8 d. After 8 d, the medium is changed to pluripotency medium for hiPSC colony stabilization and growth for another 7-9 d. The RNA mix of the reprogramming kit used in this protocol includes three components 7 : NM-RNA of the four Yamanaka factors (OCT4, SOX2, KLF4, c-MYC), plus NANOG, and LIN28; NM-RNA encoding E3, K3, and B18R for evasion of the immune response and to overcome RNAmediated toxicity; and double-stranded miRNAs from the 302/367 cluster. An increasing dose of the RNA mix is used in transfections from day 1 to day 8 to keep the transfected factor expression in the growing cell population high while avoiding toxicity. The overall goal is to maintain approximately constant amounts of RNA transfected per cell.
In the 'Quality control of main reagents' section, we give suggestions for checking that reagents are working and that cells are properly transfected. This could also be useful in investigations of possible differences in the performance of critical reagents as a consequence of batch variation. [11] [12] [13] [14] [15] and extraction of the hiPSC colonies (Step 27) After progressive morphological changes that occur during reprogramming, at day 14 the presence of TRA-1-60 + hiPSC colonies can be verified by live staining, and the reprogramming efficiency can be quantified (Fig. 4) . Colonies need to grow for an additional 2 d to become larger before isolation.
Identification (Steps
Depending on the specific application, the colonies formed in a microfluidic chamber can be isolated as a pool or as mechanically picked single colonies (Fig. 5 and Supplementary Video 2) , and replated in standard wells for expansion 9 and characterization 20 . The first method of passaging, based on EDTA, is less time-consuming but pools together all the colonies from a single culture chamber. Mechanical picking is more time-consuming and contaminates the hiPSCs with some fibroblasts (which can be removed at subsequent passages), but allows a single colony to expand. The success rate of replating the picked colonies depends on multiple factors, such as the size of cell clusters and the coating of the destination dish, as in standard hiPSC passaging.
Level of expertise
Microfluidic device production requires the use of photo-and soft-lithographic techniques, as well as equipment not commonly available in a biological laboratory, but it can be easily outsourced. However, if the equipment is available, a graduate student can master these skills after 6 weeks of training (Box 1). Training in microfluidic cell culture, described in Box 2, requires one to three experiments to develop adequate competence, and does not necessitate prior knowledge of microscale technologies. For the fibroblast reprogramming protocol (Steps 1-27), a biological background with cell culture experience is sufficient. For characterization and passaging of the obtained hiPSC colonies, following established methods that have been described previously 9, 20 , pluripotent stem cell biology skills are required. Vitronectin coating is applied when the culture chamber is still empty. To ease the inflow of protein solution, the pipette tip should go precisely inside the inlet hole. A volume of 12 µL is sufficient to fill the chamber and avoid bubble formation in the chamber due to evaporation during the 60-min incubation at room temperature. At the end of the incubation period, the protein solution is replaced with fresh medium, which is left in the chamber until cell seeding, usually within an hour. Part of the solution in the reservoir, containing a mixture of Vitronectin solution and medium, is aspirated, without completely emptying the reservoir. c, During cell seeding, the pipette tip should be placed precisely inside the inlet hole. 12 µL of well-mixed cell suspension should be injected by quick pipetting. The reservoir will be full at the end of seeding, and it is possible that a small amount of medium will be left at the inlet; it is convenient to avoid aspirating this medium, to obtain spatially homogeneous seeding along the culture chamber. d, During medium changes in the next days, the strategy that minimizes bubble formation and time consists of injecting 12 µL of medium near the inlet; because the reservoir is almost full, a droplet of medium is formed at the inlet. Repeat this operation for all the chambers of the chip. Then, using a 200-µL pipette, aspirate from each reservoir the amount of medium that is necessary to have all the medium at the inlet entering the chamber (it enters by capillarity). e, Unlike during medium change, during transfection it is extremely important that the transfection solution go completely inside the channel immediately to avoid inhomogeneities of cell transfection and toxicity. Thus, the reservoir should be emptied first, almost completely, and the transfection solution should then be injected near the inlet. Letting the solution enter the channel via capillarity guarantees an approximately constant flow rate during successive medium changes and transfections. f, Images of two stages during medium change: delivery of 12 μL of medium to the inlet of the culture chamber (left), and medium removal at the outlet/reservoir (right). Note that during medium removal the microfluidic chip is rotated by 180°. The two insets highlight the inlets of the channel after medium delivery and after medium entrance into the channel by capillarity. See also Supplementary Video 1. g, Time course of fibroblast morphology during proliferation within a microfluidic chamber at days (D) 1, 2, 4, 6, and 8 after seeding at 60 cell/mm 2 . , cell clusters at different compacting stages (D5 and D8), emerging hiPSC colonies (D10). TRA-1-60 live staining confirms the expression of this marker by newly formed hiPSC colonies by fluorescence microscopy (D11; scale bar, 100 µm). c, Top, representative image of immunofluorescence analysis of a whole culture chamber after 14 d of fibroblast reprogramming. We created the figure by tiling single microscopy images next to each other (scale bar, 1 mm). Bottom, enlargement of the region highlighted by the red frame in the whole-chamber image, assayed for Hoechst (blue), NANOG (red) and TRA-1-60 (green; scale bar, 100 µm). d, Dot plot indicating the number of hiPSC colonies obtained from each independent microfluidic culture chamber from the indicated fibroblast cell lines and using the indicated supplements. The superimposed red bars represent mean ± s.d. of the data. The number of replicates, n, is also indicated for each condition. e, Top, representative image of immunofluorescence analysis of TRA-1-60 in a culture chamber in which fibroblasts were reprogrammed in the presence of Human iPS Reprogramming Boost Supplement II for 14 d (scale bar, 1 mm). Bottom, enlargement of the region highlighted by the red frame in the top image, assayed for Hoechst (blue), NANOG (red) and TRA-1-60 (green; scale bar, 100 µm).
Materials Biological materials
• Human fibroblasts (we have successfully used BJ cells (ATCC, cat. no. CRL-2522) and HFF-1 cells (ATCC, cat. no. SCRC-1041)) ! CAUTION The cell lines used in your research should be regularly checked to ensure that they are authentic and are not infected with mycoplasma. Cut path:
Step 1 Step 2 Step 3 Step 4 Chip cutting Chamber top removal hiPSC colony picking 100 μm 
Box 1 | Microfabrication • Timing~9 h
The first three substeps shown in the workflow in Fig. 2 refer to the stages required to fabricate the final microfluidic setup used in reprogramming experiments. The techniques involved are well established in the field, and we refer the reader to a published protocol for details on replica molding (REM) for fabrication of microfluidic devices in PDMS 19 . We discuss how to adapt the protocol to the specific device used in this work. Reagents and equipment are listed in the Materials section of the main Procedure.
Procedure
1 Photomask design (Step 1 in ref. 19 ). This step is necessary only if specific modifications to the layout proposed here are needed. The photomask for this protocol is provided as a high-resolution Supplementary Manual. The layout is described in Supplementary Fig. 2 . 2 Master mold fabrication (Steps 4 and 6 in ref. 19 ). This step requires photolithography to fabricate a master with a 200-µm-high pattern, using negative SU-8 2100 resist. This mold can be used several times. c CRITICAL STEP Repeat Step 6 in ref. 19 every 10-15 uses of the mold for PDMS device production, to preserve it for long-term use. 3 To produce the microfluidic device (Steps 7-11 in ref. 19 ), use Sylgard 184 PDMS in a 10:1 base:curing-agent ratio in order to obtain PDMS stamps of ∼3-mm thickness. 4 Use disposable 1-and 3-mm biopsy punches to produce each culture chamber inlet and outlet hole, respectively, as shown in Fig. 1b . 5 Thoroughly clean a microscopy glass slide with MICRO-90 cleaning solution (2% (vol/vol) in distilled water) and rinse with distilled water. Alternatively, a rectangular glass coverslip can be used; in this case, cleaning is not needed. 6 Attach the patterned PDMS to a dry, clean glass slide, using an oxygen plasma cleaner in ref. 19 ). 7 Cool the bonded microfluidic device to room temperature (25°C). 8 Pipette 20 µL of isopropanol into each culture chamber to clean the chamber of production process byproducts, and rinse by flowing 30 µL of distilled water into the chambers before isopropanol evaporation. 9 Dry the chambers by aspirating the water with a 200-µL pipette and package the microfluidic device inside an autoclave bag. 10 Autoclave at 121°C for 15 min, and let dry afterward. • SYLGARD 184 silicone elastomer kit (Dow Corning) c CRITICAL The SYLGARD 184 silicone elastomer kit enables long-term cell culture; other elastomeric silicones are untested, and users should check to make sure they will work with the protocol.
• StemMACS mRNA transfection kit (Miltenyi, • eGFP mRNA (optional) (Stemgent, c CRITICAL eGFP mRNA can be used during the protocol to visualize the transfection efficiency.
• StemRNA-NM reprogramming kit (Stemgent, cat. no. 00-0076) c CRITICAL Conditions for using other commercially available RNA-NM reprogramming kits or custom-made RNA need to be optimized because they could have a strong effect on the reprogramming efficiency.
• RNaseZap RNase decontamination solution (Invitrogen, cat. no. AM9780)
Box 2 | Fibroblast culture in microfluidics • Timing 3-4 h
Before using the microfluidic setup for cell reprogramming, it is useful to first test that the system allows fibroblast expansion. This test has two purposes: (i) to allow the user to become familiar with cell seeding and liquid handling in the microfluidic device, and (ii) to confirm that there are no problems with the device. Reagents and equipment are listed in the Materials section of the main Procedure. Procedure 1 Prepare a vitronectin solution of 25 µg/mL in DPBS under sterile conditions and warm it to room temperature. Prepare 12 µL of solution per culture chamber, with an additional 10% excess volume. Alternatively, for fibroblast culture only, a fibronectin solution of 25 µg/mL in DPBS can be used. c CRITICAL STEP For long-term culture, the quality of the glass surface coating is critical, and high-quality recombinant proteins, such as vitronectin, reduce experimental variability. 2 Under a laminar flow hood, extract a ten-chamber microfluidic chip from its sterile packaging, using sterile tweezers, and place it inside a 100-mm-diameter Petri dish. 3 Pipette 12 µL of vitronectin solution into each (empty) chamber, ensuring that the pipette tip is properly placed inside the 1-mm-diameter inlet before injection (Fig. 3b) . 4 Add 1.5 mL of DPBS, optionally supplemented with penicillin-streptomycin, to the dish, around the microfluidic chip. 5 Incubate for 1 h at room temperature. 6 Pipette 12 µL of DMEM with 10% (vol/vol) FBS (or other fibroblast medium), optionally supplemented with penicillin-streptomycin, into each chamber, ensuring that the pipette tip is properly placed inside the 1-mmdiameter inlet before injection (Fig. 3b) . 7 Aspirate the mixture of vitronectin solution and medium from the reservoir, avoiding complete emptying (Fig. 3b) . Make sure there are no bubbles at the inlet after this procedure.
j PAUSE POINT The chip can be left under the hood in this state for~1 h before cell seeding. Place it at 4°C
for longer periods of time, preferably <~12 h. Bring it back to room temperature before cell seeding. 8 Prepare a cell suspension by detaching the fibroblasts from the previous culture dish and resuspending them in DMEM with 10% (vol/vol) FBS (or another fibroblast medium), according to standard biological practice.
To seed cells at 60 cell/mm 2 , a cell concentration in suspension of 300 cell/µL is required. Prepare 12 µL of solution per culture chamber, with an additional 10% excess volume. 9 Pipette 12 µL of well-mixed cell suspension into each chamber, ensuring that the pipette tip is properly placed inside the 1-mm-diameter inlet before injection. The injection should be performed quickly to guarantee spatial cell homogeneity along the microfluidic chamber (Fig. 3c) . 10 Place the dish containing the seeded microfluidic chip in an incubator at 37°C and 5% (vol/vol) CO 2 . 11 After 24 h and approximately every 12 h after that, replace the medium in the microfluidic chambers with prewarmed fibroblast medium. For medium changes, deposit a 12-µL droplet at the inlet without pipetting inside the chamber; repeat the operation for each chamber of the chip; last, with a p200 pipette, aspirate the medium from each reservoir to let the medium enter the chambers by capillarity (Fig. 3d ,f and Supplementary Video 1). c CRITICAL STEP If medium changes every 12 h are not possible, avoid exceeding 15 h without a medium change. 12 Add 1 mL of sterile water, optionally supplemented with penicillin-streptomycin, to the dish, around the microfluidic chip, when the DPBS added at step 4 dries out. 13 Use phase-contrast microscopy to observe the fibroblast growth during culture for a few days (Fig. 3g ).
• Polystyrene tissue culture-treated six-well plates (BD Falcon, cat. no. 353046) • Polystyrene tissue culture-treated 24-well plates (BD Falcon, cat. no. 353047)
• 100-mm-diameter Petri dish
Reagent setup
Preparation of the RNA mix for reprogramming Thaw the three vials of NM-RNAs provided in the StemRNA-NM reprogramming kit (OSKMNL NM-RNA, EKB NM-RNA, and NM-miRNAs) and prepare the RNA mix according to the manufacturer's instructions. The daily RNA mix used for reprogramming a ten-chamber microfluidic chip ranges from 0.9 to 1.9 µL (Table 1) . We suggest preparing 2-µL aliquots in sterile RNase-free microcentrifuge tubes, so that a fresh aliquot can be thawed each day. Store the aliquots at −80°C for up to 3 months. During reprogramming, thaw the required vials on ice and do not refreeze. c CRITICAL First, use RNase ZAP to clean all the surfaces of the laminar flow hood; use RNase-free sterile 0.2-mL microcentrifuge tubes and RNase-free sterile aerosol-barrier tips. Keep the RNA mix on ice at all times.
Quality control of main reagents
The quality control steps we describe here are optional and are useful for verifying the quality of the main reagents. They can be performed either before starting the actual reprogramming experiment or for troubleshooting an unsuccessful experiment. In the first check, start a reprogramming experiment but stop ∼24 h after the fourth transfection. Verify robust expression of the encoded proteins by immunocytochemistry ( Supplementary Fig. 3a ) and western blotting (Supplementary Fig. 3b) . Testing of all six transcription factors is rarely needed; the pluripotency-related transcription factors (OCT4, NANOG, SOX2) should be given priority. At this point, cells should have already downregulated the fibroblast marker vimentin (VIM), which can also be assayed by western blotting (Supplementary Fig. 3b ). As variations in transfectability may exist in different cell lines, mRNA encoding green fluorescent protein (GFP) can be added to the transfection solution, and its induced expression can be verified by fluorescence microscopy starting 24 h after the first transfection.
Procedure
Cell seeding and RNA transfections • Timing~9 d 1 Prepare the ten-chamber microfluidic devices according to Box 1. 2 Day 0, at 2 PM. Carry out Steps 1-10 of Box 2 to seed human fibroblasts to be reprogrammed in microfluidics, and place them in an incubator set to hypoxic conditions (37°C, 5% (vol/vol) CO 2 , 5% (vol/vol) O 2 ) overnight. The incubator used should be set to hypoxic conditions for the whole duration of the experiment. c CRITICAL STEP In parallel, we recommend seeding a few channels with fibroblasts that will not be transfected, as a control for any morphological changes that occur during reprogramming. 10 On days 9-15, replace the medium in the morning (~9 AM) and at night (~7 PM) with 12 µL per chamber of hiPSC expansion medium (e.g., StemMACS iPSBREW XF or E8 medium). 11 When hiPSC colonies start to be visible (~days [10] [11] [12] [13] [14] , verify the expression of the pluripotency marker TRA-1-60 by live staining. To do this, first prepare a solution of Stemgent StainAlive TRA-1-60 antibody at 5 µg/mL and inject 12 µL per chamber. 12 Incubate the cells for 30 min in the incubator. 13 Inject 12 µL of medium per chamber and incubate for 5 min. 14 Repeat Step 13 twice. 15 Observe the culture chambers by fluorescence microscopy (excitation/emission: 488/525) (typical results can be seen in Fig. 4b ). 16 Continue culture as described in Step 10.
Immunostaining for pluripotency markers in microfluidics • Timing~2 d c CRITICAL The overall workload for immunofluorescence assay in microfluidics is similar to that in standard wells. 17 After hiPSC colony identification, some chambers can be used for hiPSC immunofluorescence characterization. Use a 12-µL volume per chamber for each of the following steps. First wash the chambers once with DPBS, and then incubate the cells with 4% (wt/vol) formaldehyde for 10 min at room temperature. 18 Wash the chambers three times for 5 min each time with DPBS. 19 Incubate the cells with blocking solution (DPBS with 10% (vol/vol) horse serum; add 0.1% (vol/vol) Triton X-100 for intracellular targets) for 45 min at room temperature. 20 Prepare final-concentration primary antibody solutions, inject into the microfluidic chambers, and incubate overnight at 4°C. We recommend using the primary antibodies listed in the Materials section 21 Wash three times for 5 min each time with DPBS.
Anticipated results
It is advisable to first set up the process using, as a standard, low-passage human-foreskin-derived fibroblasts, such as BJ or HFF-1 cells. This protocol is effective in obtaining hiPSC colonies in every culture chamber. The timing of the morphological changes of cells during reprogramming, from acquisition of an epithelial morphology to compaction of hiPSC colonies, is shown in Fig. 4 . By days 3 and 4, cells start to change morphology toward an epithelial-like state, which is acquired by day 7. Between days 8 and 10, small clusters of epithelial cells start to emerge. Defined cell nuclei are visible with evident nucleoli. We found that on day 14, BJ reprogramming efficiency was 52 ± 5 TRA-1-60 + colonies per chamber (mean ± s.d., n = 60), as shown in Fig. 4c and quantified in Fig. 4d (also see the Source Data). The reprogramming efficiency can be further increased by the addition of previously reported reprogramming boosters. As proof of concept, we report the use of LSD1 inhibitor 21 (efficiency = 70 ± 5 colonies per chamber, mean ± s.d., n = 24) or a cocktail of sodium butyrate 22 , PS48 23 , and TGF-β RI kinase inhibitor IV 24 (efficiency = 160 ± 20 colonies per chamber, mean ± s.d., n = 48) ( Fig. 4d and Source Data).
Reprogramming in E6 supplemented with FGF2 (100 ng/mL), without the addition of other reprogramming boosters, is less efficient than reprogramming in Pluriton medium: BJ efficiency is 19 ± 4 TRA-1-60 + colonies per chamber (mean ± s.d., n = 5), and HFF-1 efficiency is 27 ± 7 TRA-1-60 + colonies per chamber (mean ± s.d., n = 10), both by day 14 ( Fig. 4d and Source Data). For improved reprogramming efficiency, if a high proliferation rate is observed in E7 medium, cells can be seeded at lower density (30 cells/mm 2 ), whereas in the case that transfections induce high toxicity, they can be kept at a low dose until cells reach~60% confluence, Typically, the transfection is switched to a medium dose at day 5 or 6 for BJ or HFF-1 fibroblasts.
From our experience, the reprogramming efficiency is very variable from cell line to cell line 2 . In the Troubleshooting section, we give some suggestions on how to handle this, by changing various factors such as cell density, RNA transfection dose, and number of transfections. Given the high throughput and low cost of microfluidics, for new primary lines we recommend testing multiple reprogramming conditions in parallel, according to the principles described in the Troubleshooting section, in one or two microfluidic devices. Following this strategy,~30% of the microfluidic chambers contain up to five colonies, which is sufficient for derivation of the few stable hiPSC lines usually required for use. Despite some flexibility being required to identify the optimal conditions, we consistently found a gain in efficiency when performing the process in microfluidics compared with that achived with standard well plates.
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